| 2026-08-06 | Press release | MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 |
| 2026-07-30 | Press release | MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies |
| 2026-07-10 | Press release | MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Thera |
| 2026-07-06 | Press release | MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addictio |
| 2026-06-25 | Press release | MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxioly |
| 2026-06-17 | Press release | MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Ne |
| 2026-06-04 | Press release | MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 |
| 2026-05-27 | Press release | MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead |
| 2026-05-14 | Press release | MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 |
| 2026-05-13 | Press release | MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addi |
| 2026-04-17 | Presentation | I Accept |
| 2026-03-23 | Press release | MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies |
| 2026-03-04 | Press release | MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 |
| 2026-02-03 | Press release | MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study |
| 2025-10-24 | Press release | MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-In |
| 2025-10-16 | Press release | MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation |
| 2025-09-30 | Press release | MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine A |
| 2025-09-22 | Press release | MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non |
| 2025-09-16 | Press release | MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals |
| 2025-09-12 | Press release | MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeuti |
| 2025-08-19 | Press release | MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, A |
| 2025-08-12 | Press release | MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy |
| 2025-07-30 | Press release | MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Stu |
| 2025-07-29 | Press release | MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain |
| 2025-07-11 | Press release | MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity |
| 2025-07-03 | Press release | MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Mo |
| 2025-06-30 | Press release | MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and |
| 2025-06-25 | Press release | MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 – A Drug Candidate Pending Acquisition &# |
| 2025-06-18 | Press release | MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journ |
| 2025-05-28 | Press release | MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program |
| 2025-05-08 | Press release | MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value B |
| 2025-05-06 | Press release | MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked |
| 2025-04-23 | Press release | MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pai |
| 2025-04-16 | Press release | MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidenc |
| 2025-04-01 | Press release | MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain |
| 2025-03-24 | Press release | MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infus |
| 2025-03-04 | Press release | MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain |
| 2024-12-19 | Press release | MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Develop |
| 2024-12-10 | Press release | MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by |
| 2024-11-20 | Press release | MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site |